One 2022 study found that patients who didn’t get adequate sleep were 1.27 times more likely to develop allergy-related outcomes, such as atopic dermatitis and asthma.

Ivarmacitinib, also known as oral SHR0302, is not yet approved by the FDA, with trials currently exploring its utility in disease settings that include atopic dermatitis and rheumatoid arthritis.

Adults with atopic dermatitis treated with upadacitinib had fewer major adverse cardiovascular events compared with background rates in real-world populations, adding to research supporting the ...

Atopic dermatitis (AD) with complex manifestations and genetic associations. Here the author profile the transcriptome of 951 skin samples from patients with AD to link skin phenotypes, clinical ...

Kymera Therapeutics, Inc. (NASDAQ:KYMR) on Monday revealed clinical results from the Phase 1 healthy volunteer study of KT-621, its first-in-class, oral STAT6 degrader medicine. The findings ...

Sun Pharma is also discontinuing studies of SCD-044 for atopic dermatitis after top-line results from a phase 2 clinical trial did not meet the primary objective of 75% improvement in EASI (Eczema ...

Approval in atopic dermatitis could unlock additional sales momentum for Zoryve, which is available in a 0.3% cream for psoriasis and a 0.3% topical foam for seborrheic dermatitis.

Pfizer could be just a few months away from getting FDA approval for its JAK1 inhibitor abrocitinib in atopic dermatitis, a drug that CEO Albert Bourla believes hasn’t been given the credit it ...

Soquelitinib Interim Data from the Atopic Dermatitis Phase 1 Clinical Trial As of May 28, 2025, enrollment in cohorts 1, 2 and 3 has been completed for a total of 48 patients and all patients ...

ENV-294, a first-in-class investigational drug with an innovative breakthrough mechanism and broad therapeutic potential, successfully cleared a key safety milestone BOULDER, Colo.--(BUSINESS WIRE ...

--Arcutis Biotherapeutics, Inc., a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will present five posters ...